Human normal immunoglobulin G (IgG)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis
Conditions
Myasthenia Gravis
Trial Timeline
Oct 1, 2014 → Oct 21, 2022
NCT ID
NCT02774239About Human normal immunoglobulin G (IgG)
Human normal immunoglobulin G (IgG) is a phase 3 stage product being developed by CSL for Myasthenia Gravis. The current trial status is completed. This product is registered under clinical trial identifier NCT02774239. Target conditions include Myasthenia Gravis.
What happened to similar drugs?
5 of 20 similar drugs in Myasthenia Gravis were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02774239 | Phase 3 | Completed |
Competing Products
20 competing products in Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| tacrolimus | Astellas Pharma | Phase 3 | 40 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 40 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 40 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 47 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 47 |
| Placebo + CFZ533 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 47 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 40 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 40 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 44 |
| Inebilizumab | Amgen | Phase 2 | 42 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 21 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 32 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 44 |
| HIZENTRA ® | CSL | Phase 2 | 35 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 21 |
| zilucoplan (RA101495) | UCB | Phase 3 | 44 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 35 |